Advanced Search

Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 1999 December;51(12) > Minerva Ginecologica 1999 December;51(12):483-500



A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index

Frequency: Bi-Monthly

ISSN 0026-4784

Online ISSN 1827-1650


Minerva Ginecologica 1999 December;51(12):483-500


Chemoresistance in ovarian cancer. State of art and perspectives

Katsaros D., Fracchioli S., Arese P., Enria R., Cassinelli P., Mingrone K., Piccinno R., Rigault De La Longrais I. A., Massobrio M.

Aim of this study was to provide a review of the basic mechanisms of drug resistance in ovarian cancer and novel strategies to modulate drug resistance. Relevant articles published through August 1999 were identified using the Medline data base. Publications identified by the search were reviewed and evaluated critically for their relevance to drug resistance in ovarian cancer. Ovarian cancer patients have high response rates to initial chemotherapy after cytoreductive surgery. However, most will develop resistance to chemotherapy during the course of their treatment. There are multiple mechanisms resulting in drug resistance. Strategies to modulate drug resistance include dose intensity, various pharmacologic agents, and gene therapy.

language: Italian


top of page